- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00064090
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies
RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and may help cytarabine kill more cancer cells by making them more sensitive to the drug.
PURPOSE: Phase I trial to study the effectiveness of combining cytarabine with 3-AP in treating patients who have relapsed or refractory hematologic cancer.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
- Determine the feasibility, tolerability, and toxic effects of 3-AP in combination with cytarabine in patients with hematologic malignancies.
- Determine the maximum tolerated dose and phase II dose of cytarabine in this regimen in these patients.
- Determine the biological effects of 3-AP and its interaction with cytarabine in these patients.
OUTLINE: This is a pilot, dose-escalation study of cytarabine.
Patients receive 3-AP IV over 6 hours followed by cytarabine IV over 18 hours on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a response may receive an additional course as consolidation therapy.
Cohorts of 3-6 patients receive escalating doses of cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 10 patients receive treatment at that dose.
PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.
Tipo de estudio
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030-4095
- University of Texas - MD Anderson Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following hematologic malignancies:
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Chronic myelogenous leukemia (CML)
- CML in blast crisis
- Chronic lymphocytic leukemia
High-risk* myelodysplastic syndromes, including the following:
- Refractory anemia with excess blasts (RAEB)
- RAEB in transformation
- Chronic myelomonocytic leukemia NOTE: *High-risk myelodysplasia defined as having an International Performance Scoring System score of at least 1.5, based on adverse cytogenetics, greater than 10% blasts in marrow, and cytopenias in at least 2 lineages
- Relapsed or refractory disease
- Ineligible for higher priority protocols
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- More than 2 months
Hematopoietic
- See Disease Characteristics
Hepatic
- Bilirubin no greater than 2.0 mg/dL (unless considered due to malignancy)
- ALT or AST no greater than 3 times upper limit of normal
- Chronic hepatitis allowed
Renal
- Creatinine no greater than 2.0 mg/dL (unless considered due to malignancy)
Cardiovascular
- No myocardial infarction within the past 3 months
- No symptomatic coronary artery disease
- No arrhythmias (other than atrial fibrillation or flutter) requiring treatment
- No uncontrolled congestive heart failure
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Concurrent infections under active treatment with and controlled by antibiotics allowed
- No other concurrent life-threatening illness
- No mental deficit or psychiatric history that would preclude giving informed consent or complying with protocol
PRIOR CONCURRENT THERAPY:
Biologic therapy
At least 1 week since prior growth factors, including the following:
- Epoetin alfa
- Filgrastim (G-CSF)
- Sargramostim (GM-CSF)
- Interleukin-3
- Interleukin-11
- No concurrent anticancer immunotherapy
Chemotherapy
- At least 72 hours since prior hydroxyurea
- Recovered from prior chemotherapy
- No other concurrent anticancer chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- At least 2 weeks since prior radiotherapy
- No concurrent anticancer radiotherapy
Surgery
- Not specified
Other
- At least 3 weeks since prior myelosuppressive cytotoxic agents (in the absence of rapidly progressing disease)
- At least 1 week since prior nonmyelosuppressive therapy
- No other concurrent standard or investigational therapy for the malignancy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- anemia refractaria con exceso de blastos
- anemia refractaria con exceso de blastos en transformación
- leucemia mielomonocítica crónica
- síndromes mielodisplásicos previamente tratados
- leucemia mieloide aguda en adultos con anomalías 11q23 (MLL)
- leucemia mieloide aguda en adultos con inv(16)(p13;q22)
- leucemia mieloide aguda en adultos con t(15;17)(q22;q12)
- leucemia mieloide aguda en adultos con t(16;16)(p13;q22)
- leucemia mieloide aguda en adultos con t(8;21)(q22;q22)
- leucemia mieloide aguda recurrente en adultos
- leucemia mielógena crónica en fase blástica
- leucemia mielógena crónica recidivante
- leucemia linfocítica crónica refractaria
- leucemia linfoblástica aguda recurrente en adultos
- neoplasia mielodisplásica/mieloproliferativa, inclasificable
- leucemia mieloide crónica atípica, BCR-ABL1 negativo
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Enfermedades de la médula ósea
- Enfermedades hematológicas
- Condiciones precancerosas
- Síndromes mielodisplásicos
- Leucemia
- Preleucemia
- Trastornos mieloproliferativos
- Enfermedades mielodisplásicas-mieloproliferativas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Citarabina
Otros números de identificación del estudio
- VION-CLI-032
- CDR0000306465 (Identificador de registro: PDQ (Physician Data Query))
- MDA-DM-030096
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .